Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  methylene blue
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)
Phase: Phase II
Type: Diagnostic
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LSU #6169, NCT00784849
Axillary Reverse Mapping
Phase: Phase II
Type: Diagnostic
Status: Closed
Age: 18 to 100
Sponsor: Other
Protocol IDs: 11737, NCT01381315
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Phase: Phase II
Type: Diagnostic
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-17-01/08, 2013-000634-35, NCT02295774
Phase I Study of Methylene Blue for the Treatment of Hypotension in Patients with Advanced Cancer Receiving IL-1A Support for CBDCA
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-9211, NCI-T92-0216N, T92-0216
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000331918, GOG-0206, NCT00070317
Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: 3157, NCT00314405
Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Phase: No phase specified
Type: Screening
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-17-01/04, NCT01520324
Start Over